Please login to the form below
Police to probe Novo Nordisk over disclosure delay
Regulator says pharma company was late to announce FDA decision to not approve Tresiba and Ryzodeg
EC fines J&J and Novartis in pay-for-delay case
Says companies delayed entry of generic painkiller
IMI launches dementia trials alliance
EU group wants to revamp approach to Alzheimer’s research
FDA panel backs Takeda's inflammatory bowel disease drug
Vedolizumab on course for US approval to treat Crohn’s disease and ulcerative colitis
This month in 1901: The first Nobel Prize awards
Serum therapy work took inaugural medicine award
Sanofi's Aubagio backed by NICE
Oral MS drug recommended for NHS use in England and Wales
Novartis' Tasigna tops Glivec in long-term trial
Boost ahead of patent expiry for leukaemia drug
AZ donates Brixham lab to Plymouth University
Will create global research and education facility
Study highlights poor diabetes consultation
Less than a third of patients asked for input into their treatment plans
Smart Glasses: A new look for healthcare?
Wearable computer devices like Google Glass are tipped to become the next big technology trend, and have exciting health applications
-
Counting what countsMeasurement is the lifeblood of communications and brand investment in analytics is poised for steep growth
-
Pharma should not ignore IndiaIt’s complicated, but multinational pharma cannot ignore a market with one billion plus people
-
AZ wins EU approval for four-strain flu vaccineFluenz Tetra offers competition to GSK’s Influsplit Tetra/Fluarix Tetra
-
Auxilium's Xiaflex cleared in US for erection disorderFDA approval to treat Peyronie's disease
-
Novartis myeloma drug clears phase III trialPanobinostat on course to be first in new class of treatment for bone marrow cancer
-
European Court may yet force AbbVie and InterMune to release dataOrders rethink on EMA's Humira and Esbriet injunction
-
Pfizer ups the ante on clinical transparencyRevamps access to data portal
-
Lilly depression drug fails late-stage trialsWill not pursue edivoxetine as an add-on treatment for depression
-
NICE wants more info on Genzyme's MS drugUK health guidance body turns down Lemtrada in draft guidance
Latest appointments
-
ABPI names NHS partnership managerRaj Tugnet will lead work to strengthen pharma/NHS collaboration in UK
-
Senior hires at Precision Health MediaNew VP for ad sales, chief financial officer ad member of the board
-
Ketchum loses healthcare headAmanda Sefton leaves to pursue “passion project” in wine trade
-
MSD appoints new UK headMike Nally moves from Swedish division
-
Pfizer's Jonathan Emms to be ABPI presidentWill take over from MSD's Deepak Khanna in April
Featured jobs
- Global Brand Manager
- flexible salary + bonus + car allowance + benefits
- Brand Director - Highly Specialised Product - Global remit
- Highly Competitive Basic, Bonus + Benefits
- Commercial Manager
- Negotiable
- Regulatory Affairs Senior Manager, CMC - 12 month cotnract
- Competitive
Subscribe to our email news alerts
PMHub
Real Science Communications
At Real Science Communications our vision is to provide excellence in healthcare communications, delivering real results for our clients.How do...
Latest intelligence
- Doctors’ disease knowledge: an insight into Latin America
- A lack of specialists outside major cities means many major illnesses go undiagnosed...
- Survey: Digital Futures 2014
- Can you help us predict pharma's digital future?...
- Adherence to treatment and side effect management in breast cancer
- The success of treatment for breast cancer is dependent on a high level of adherence, however it is surprisingly common for women with breast cancer to miss doses or stop...
Quick links
